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–32%, p=0·0008). These phenotypic diﬀ erences, in 
combination, could help to explain why south Asian 
individuals are more susceptible to the adverse metabolic 
eﬀ ects of a diet that is both high in fat and energy. 
Notably, south Asians in the study were shorter and 
lighter than their Caucasian counterparts, and thus had 
the same BMI. 
Several important questions arise from this study,6 
including what is the exact diﬀ erence in molecular 
composition of BAT between these ethnic groups and 
when these eﬀ ects ﬁ rst become apparent. The stage of 
life point is especially intriguing because another study 
has recently shown that when BAT function is assessed 
with thermal imaging, children (aged 6–11 years) who 
were non-Caucasian (but born in the UK) had more BAT 
than did white Caucasians.8 Thus, whether changes in 
BAT growth and development through childhood and 
adolescence contribute to diﬀ erences seen in young 
adulthood needs to be addressed. Such eﬀ ects might 
not be conﬁ ned to BAT because south Asians have a 
diﬀ erent overall growth trajectory, as indicated by adult 
bodyweight and height, which are both substantially 
lower than other populations (thus reﬂ ecting a diﬀ erent 
genotype as well as phenotype). Other factors that would 
be expected to aﬀ ect BAT could include variations in the 
thermal environment and diet.7 Molecular characteristics 
of BAT could oﬀ er further insights into the present 
controversy as to the diﬀ erent developmental origins of 
brown and white adipocytes and the relative contribution 
of beige adipose tissue to energy balance.9 Finally, once 
BAT is lost (especially in early life) the question remains 
as to whether it can ever be reactivated or synthesised in 
suﬃ  cient amounts to aﬀ ect whole-body energy balance.
As south Asians are much more susceptible to 
metabolic disturbances such as obesity and diabetes, 
it is important to establish whether these individuals 
are resistant to established stimulators of BAT 
thermogenesis such as chronic cold exposure or dietary 
stimulants like capsaicin.10 This group is now the ideal 
target for new pharmacological interventions that might 
oﬀ er proof-of-principle that enhanced BAT volume or 
function can have long-term health beneﬁ ts against 
metabolic disease.
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 Stemming the tide of type 2 diabetes and its consequences 
in south Asian individuals
Globally, individuals of south Asian descent have increased 
susceptibility to type 2 diabetes.1 By age 80 years, 50% of 
south Asian migrants to the UK have diabetes,2 with a 
younger age of onset and greater eﬀ ect on cardiovascular 
outcomes than European comparators.3
What can be done to stem this tide? The Indian 
Diabetes Prevention Programme,4 which studied more 
than 500 people with impaired glucose tolerance, 
showed a reduction of more than 25% in diabetes 
incidence over 2·5 years in those randomised to a lifestyle 
intervention or metformin, alone or in combination, 
compared with control. In the lifestyle intervention 
group, no weight loss was noted and increased physical 
activity seemed to account for the beneﬁ cial eﬀ ects.4 
In The Lancet Diabetes & Endocrinology, Raj Bhopal 
and colleagues5 report outcomes of a family-based 
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intervention (PODOSA) in south Asian individuals 
with impaired glucose tolerance or impaired fasting 
glucose, living in the UK. This family-cluster randomised 
controlled trial was initially designed with incidence of 
diabetes at 3 years as its primary endpoint. Participants 
were randomised to an intensive lifestyle intervention 
(15 dietitian visits focussed on diet and physical 
activity) or control group (four dietitian visits with 
standardised advice on diet and physical activity). The 
intervention was culturally adapted and its acceptability 
to participants is borne out by impressive retention over 
3 years. However, in view of unforeseen diﬃ  culties in 
recruitment of the planned 540 participants (because the 
frequency of impaired glucose tolerance and impaired 
fasting glucose was lower than expected), after 2 years 
of recruitment the primary endpoint was changed to 
weight loss, and only 171 participants were enrolled. 
At 3 years, there was a small reduction in weight in the 
intervention group compared with the control group 
(adjusted mean diﬀ erence –1·64 kg [95% CI –2·83 to 
–0·44]). Although more participants in the intervention 
group lost weight, about 20% of participants in both 
groups gained more than 2·5 kg in weight. The number 
of participants achieving the recommended level 
of physical activity (≥30 min per day) did not diﬀ er 
signiﬁ cantly between groups (odds ratio [OR] 1·14 
[95% CI 0·53–2·47]). While underpowered for this 
outcome, there was a suggestion of reduced incidence 
of diabetes in the intervention group compared with the 
control group (OR 0·68 [95% CI 0·27–1·67]). 
Having engaged a south Asian population in PODOSA, 
it would have been informative to include an objective 
assessment of physical activity using monitors. 
Ad di tion ally, further useful information could have 
been gained with the inclusion of outcomes such as 
insulin concentration and bioimpedance measures of 
body fat and lean mass, which are simple and cost little 
to implement.
PODOSA showed that in a high-risk group of south 
Asian individuals, a lifestyle intervention resulted in 
weight loss. Could the modest weight loss achieved 
in PODOSA result in reduced progression to diabetes? 
Both the Finnish6 and US7 diabetes prevention trials 
(the former wholly, the latter largely consisting of 
participants of European origin), reported substantial 
reductions in progression to diabetes in response to 
lifestyle intervention. In both these trials, participants in 
the intervention groups achieved signiﬁ cant weight loss 
compared with those in the control groups (3·5 kg and 5·5 
kg respectively), and major increases in physical activity.  By 
contrast, in the Indian Diabetes Prevention Programme,6 
although participants in the lifestyle intervention group 
had substantially reduced progression to diabetes, they 
had no diﬀ erence in weight change compared with 
participants in the control group. However, adherence 
to an exercise regimen requiring 30 min or more of daily 
brisk walking increased from 42% to 59%. It is surprising 
that PODOSA, with little change in physical activity, also 
hints at reduced progression to diabetes in response to 
lifestyle intervention (OR 0·68). But conﬁ dence limits 
around this estimate are wide (95% CI 0·27–1·67), and 
consistent with both a beneﬁ cial and harmful eﬀ ect of the 
intervention, reﬂ ecting the too small sample size for this 
outcome, so that no deﬁ nitive conclusions can be drawn. 
Alternatively, if the hint towards a reduction in diabetes is 
real, people from south Asia might be more responsive, in 
terms of diabetes progression, to weight loss than people 
of European origin. This intriguing hypothesis requires 
testing, and the planned longer term follow up of PODOSA 
could begin to address this question.
What are the next steps for diabetes prevention 
research? In view of the fact that half of south Asian 
migrants will develop diabetes, many in early adulthood, 
an approach that targets high-risk individuals in late 
adulthood might be unrewarding. Additionally, there 
is evidence for transgenerational transmission of 
diabetes risk.8 Future trials could adopt the family-based 
approach tested successfully in PODOSA, but recruit 
from the entire south Asian population and provide 
lifestyle advice to all, coupled with a more intense 
intervention, including medication, for those at highest 
risk (eg, overweight, family history).   
Substantial lifestyle changes are diﬃ  cult to maintain 
long term. Crucial periods of development have been 
identiﬁ ed that strongly contribute to adult disease, 
including pregnancy, infancy, and adolescence.9 
Animal and limited human data suggest that short-
term interventions, including drugs, during these 
periods might greatly reduce or even eliminate the 
risk of disease.10,11 Exploration of the eﬀ ect of brief 
interventions during key periods of development oﬀ ers a 
methodologically challenging, but potentially rewarding, 
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Ultimately, the goal of any diabetes prevention 
strategy is to reduce the burden of complications and 
especially cardiovascular disease, which causes the 
most morbidity and mortality, and to which south 
Asian individuals are particularly susceptible. Endpoints 
should include cardiovascular risk factors and subclinical 
cardiovascular disease. Consideration of multiple risk 
factors should be as embedded in prevention trials as it 
now is in clinical practice. 
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Cognitive decline in type 2 diabetes
Evidence is accumulating that type 2 diabetes is associated 
with cognitive impairment and dementia. In individuals 
older than 60 years, 7–13% of dementia cases are 
estimated to be attributable to diabetes,1 and the number 
of cases of diabetes-associated dementia is expected to 
increase because of the diabetes pandemic and ageing 
populations worldwide. Dementia is preceded by 
accelerated cognitive decline, and study of the risk factors 
for cognitive decline could therefore provide insights into 
the causes of dementia. However, the natural history of 
cognitive decline in type 2 diabetes is not well understood. 
Some researchers have suggested that clinically relevant 
cognitive decline related to type 2 diabetes does not 
develop until the neurodegenerative changes in the brain 
associated with ageing have started to occur (ie, after age 
60 years).1 Additionally, in some studies2,3 the extent of 
cognitive decline in new-onset diabetes was not clearly 
diﬀ erent from that in individuals without diabetes, 
suggesting a threshold fo r diabetes duration in the 
association between cognitive decline and diabetes. 
Against this background, Richard Tuligenga and 
colleagues’ analysis4 from the Whitehall II cohort study 
in The Lancet Diabetes & Endocrinology addresses the 
questions of whether type 2 diabetes is associated 
with cognitive decline before old age, and whether 
glycaemic control and disease duration are risk factors 
for faster cognitive decline. The investigators compared 
cognitive decline over 10 years between individuals with 
normoglycaemia, prediabetes, new-onset diabetes, and 
known diabetes; the known diabetes group had a mean 
age of 57·4 years—much younger than in previous studies 
(69–74 years).2,5,6 They report that diabetes was associated 
with accelerated cognitive decline and that both disease 
duration and glycaemic control (assessed by HbA1c) were 
important risk factors. A strength of the present study is 
that it explicitly compares the eﬀ ect of diabetes with that 
of age. Cognitive decline in middle-aged individuals with 
diabetes was 1·24–1·45 times faster than that in normal 
ageing (ie, those with known diabetes had a 45% faster 
decline in memory [10 year diﬀ erence in decline –0·13 SD, 
95% CI –0·26 to –0·00; p=0·046] and a 24% faster decline 
in global cognitive score [–0·11 SD, –0·21 to –0·02; 
p=0·014]), which seems less than that in previous studies 
(1·5–2·0).7 Because most previous studies were done in 
older individuals with diabetes, these ﬁ ndings suggest 
that the eﬀ ect of diabetes on cognitive decline might 
accelerate with age. Thus, 10 years of diabetes could 
be calculated to correspond to 2·5–10 years of extra 
